Tofacitinib vs placebo
Serious adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in serious adverse events (5 mg/10 mg) compared with placebo (low certainty).
1 finding from 1 review
- Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyRR 0.81 [0.42, 1.59]1 study · 592 participantsLow